Point72 Asset Management L.P. Purchases 83,770 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Point72 Asset Management L.P. grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 119.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 154,022 shares of the medical research company’s stock after acquiring an additional 83,770 shares during the quarter. Point72 Asset Management L.P. owned 0.31% of Charles River Laboratories International worth $44,640,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the business. Eaton Vance Management bought a new stake in Charles River Laboratories International in the 1st quarter worth approximately $73,000. Amundi Asset Management US Inc. increased its stake in Charles River Laboratories International by 9.8% in the 1st quarter. Amundi Asset Management US Inc. now owns 114,950 shares of the medical research company’s stock worth $33,316,000 after acquiring an additional 10,244 shares during the last quarter. Maverick Capital Ltd. bought a new stake in Charles River Laboratories International in the 1st quarter worth approximately $1,420,000. Tudor Investment Corp Et Al increased its stake in Charles River Laboratories International by 55.7% in the 1st quarter. Tudor Investment Corp Et Al now owns 13,786 shares of the medical research company’s stock worth $3,996,000 after acquiring an additional 4,934 shares during the last quarter. Finally, Sandler Capital Management increased its stake in Charles River Laboratories International by 5.5% in the 1st quarter. Sandler Capital Management now owns 198,321 shares of the medical research company’s stock worth $57,479,000 after acquiring an additional 10,280 shares during the last quarter. 92.50% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently weighed in on CRL shares. Credit Suisse Group boosted their target price on Charles River Laboratories International from $352.00 to $385.00 and gave the company a “neutral” rating in a research report on Tuesday. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $361.00 target price on the stock in a research report on Tuesday, May 18th. JPMorgan Chase & Co. upped their price objective on Charles River Laboratories International from $375.00 to $390.00 and gave the company an “overweight” rating in a research report on Friday, May 28th. Deutsche Bank Aktiengesellschaft upped their price objective on Charles River Laboratories International from $334.00 to $354.00 and gave the company a “buy” rating in a research report on Wednesday, May 5th. Finally, Truist Securities upped their price objective on Charles River Laboratories International from $324.00 to $369.00 and gave the company a “buy” rating in a research report on Tuesday, May 25th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $347.85.

Charles River Laboratories International stock opened at $385.77 on Thursday. The company has a 50-day simple moving average of $354.90. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.53 and a current ratio of 1.77. Charles River Laboratories International, Inc. has a one year low of $192.13 and a one year high of $386.57. The stock has a market capitalization of $19.38 billion, a PE ratio of 52.27, a PEG ratio of 2.76 and a beta of 1.14.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Monday, May 3rd. The medical research company reported $2.53 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.34. Charles River Laboratories International had a return on equity of 22.54% and a net margin of 12.33%. The company had revenue of $824.60 million during the quarter, compared to analysts’ expectations of $798.52 million. During the same period last year, the business posted $1.84 earnings per share. The firm’s revenue was up 16.6% compared to the same quarter last year. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.99 EPS for the current fiscal year.

In other Charles River Laboratories International news, CEO James C. Foster sold 7,500 shares of the stock in a transaction that occurred on Friday, May 7th. The stock was sold at an average price of $343.17, for a total transaction of $2,573,775.00. Following the transaction, the chief executive officer now owns 221,088 shares in the company, valued at $75,870,768.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael Gunnar Knell sold 800 shares of the stock in a transaction that occurred on Thursday, June 3rd. The stock was sold at an average price of $329.76, for a total value of $263,808.00. Following the transaction, the chief accounting officer now owns 4,563 shares in the company, valued at approximately $1,504,694.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 24,923 shares of company stock valued at $8,397,380. 1.20% of the stock is currently owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: What is insider trading?

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.